Bria-IMT Vaccine + Pembrolizumab Shrinks Brain Mets in 5 of 6 Patients; Tumor-Agnostic Basket Trial Launches
- Trial ID
- NCT06072612 on ClinicalTrials.gov
- Cancer type
- Breast Cancer: Brain Mets
- Published in
- New in Oncology - July 3, 2025
Bria-IMT—an irradiated, GM-CSF–secreting allogeneic breast-cancer cell line (SV-BR-1-GM) that functions as an antigen-presenting vaccine—is moving into the single-site ASTRO-VAC CNS phase 1 basket (NCT06072612) after earlier phase 1/2 work showed intracranial lesion reductions in 5/6 evaluable metastatic-breast-cancer patients (median −60%, range −42% to −100%) and 40% disease control post-ADC therapy, with manageable safety. The new study pairs Bria-IMT with pembrolizumab for solid-tumor brain-met patients progressing after standard care; key read-outs will be intracranial disease-control and radiographic PFS.
Take home
Encouraging 83% early breast cancer brain-met control justifies this basket approach, but with only six prior patients the vaccine still needs to prove durability and activity before it can claim a CNS niche.
More on NCT06072612
More in breast cancer
-
Trial result · Oct 22, 2026 · NCT02364557
NRG-BR002: Metastasis-directed ablation (SBRT/surgery) fails to extend PFS in oligometastatic breast cancer on 1L systemic therapy -
Trial result · Oct 22, 2026 · NCT05963984
Samuraciclib + fulvestrant shows higher clinical benefit and numerically longer PFS after CDK4/6 inhibition in randomized Phase 2 breast cancer trial -
Trial result · Oct 15, 2026 · NCT05306340
Giredestrant (oral SERD) + everolimus improves PFS after CDK4/6 inhibition, with the strongest benefit in ESR1-mutated breast cancer -
Trial result · Oct 15, 2026 · NCT02264678
Ceralasertib (ATR inhibitor) + Olaparib (PARP inhibitor) hits 37.8% ORR in PARPi‑naïve BRCA‑mut HER2‑neg breast cancer -
New trial · Oct 15, 2026 · NCT07844759
Pilot study tests single-fraction stereotactic radiation plus endocrine therapy without lumpectomy in early breast cancer